Coagulation factor VIIa-tissue factor complex (FVIIa/TF complex)

The Coagulation factor VIIa-tissue factor (FVIIa/TF) complex, also known as the extrinsic tenase complex, is the primary physiological initiator of the blood coagulation cascade. It forms when vascular injury exposes subendothelial Tissue Factor (TF) to circulating Factor VII or its activated form, Factor VIIa [1][2]. This binding dramatically increases the enzymatic activity of FVIIa, enabling it to proteolytically activate Factor X and Factor IX, which ultimately leads to a burst of thrombin generation and the formation of a stable fibrin clot [3][4]. Beyond its critical role in hemostasis, the FVIIa/TF complex triggers intracellular signaling through the cleavage of Protease-Activated Receptors (PARs), influencing pathological processes such as tumor metastasis, angiogenesis, and chronic inflammation [5]. Therapeutically, recombinant FVIIa is used to treat bleeding in hemophilia patients with inhibitors, while inhibitors of the FVIIa/TF complex are investigated as potent anticoagulants for treating thrombosis and potentially as anti-tumor agents [1][5]. Citations: [1] https://www.ncbi.nlm.nih.gov/books/NBK507850/ [2] https://www.uniprot.org/uniprotkb/P13726/entry [3] https://www.uniprot.org/uniprotkb/P08709/entry [4] https://pubmed.ncbi.nlm.nih.gov/12859597/ [5] https://pubmed.ncbi.nlm.nih.gov/22239918/

Other names

Extrinsic tenase complexFactor VIIaTissue factorCoagulation factor IIICD142F7/F3 complexThromboplastin

Inhibition of the catalytic activity of the FVIIa/TF complex to prevent the activation of Factor X and Factor IX, or the use of recombinant FVIIa to bypass deficiencies in the intrinsic pathway to promote thrombin generation.